Experts from the American College of Rheumatology (ACR), FDA, and other leading national healthcare groups spoke about the emerging biosimilars market, including key policy and regulatory questions for patients, providers, and the healthcare system, during a national policy briefing held by the nonpartisan Alliance for Health Reform. Dr. Angus Worthing, MD, FACR, FACP, who spoke on behalf…